Semaglutide
Also known as: Ozempic, Wegovy
Brand names: Ozempic, Wegovy, Rybelsus, Oral Wegovy
Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. In August 2025, it received accelerated approval for MASH (metabolic-associated steatohepatitis) with liver fibrosis. An oral formulation (Oral Wegovy) was approved in December 2025, launching in January 2026. Clinical trials demonstrated an average weight loss of 15% over 68 weeks with injectable Wegovy, and 16.6% with oral Wegovy. The medication works by mimicking GLP-1, a natural hormone that regulates blood sugar and appetite.
GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow gastric emptying, and reduce appetite
| Parameter | Detail |
|---|---|
| Administration | Subcutaneous injection |
| Typical Dose | 2.4mg weekly (Wegovy dose) |
| Frequency | Weekly |
Common Side Effects
Serious Side Effects
- Personal or family history of medullary thyroid carcinoma
- Multiple endocrine neoplasia syndrome type 2
- Pregnancy
Evidence Quality
Clinical Trial Phase
Approved (post-market)
Average Weight Loss in Trials
15%
| Peptide | Monthly Cost | FDA Status |
|---|---|---|
| Semaglutide | $1000 - $1400/mo | FDA Approved |
| Tirzepatide | $1100 - $1100/mo | FDA Approved |
| Retatrutide | $1200 - $1500/mo | Phase 3 (NDA expected late 2026) |
| AOD-9604 | $30 - $60/mo | Phase 2 (failed; reclassification pending) |
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy or medication. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary.